Formulation and Efficacy of Liposome-encapsulated Afatinib for Therapy of Non-small Cell Lung Cancer

Formulation and Efficacy of Liposome-encapsulated Afatinib for Therapy of Non-small Cell Lung Cancer

Background and objective Afatinib, a second-generation irreversible epidermal growth factor inhibitor receptor for the development of non-small cell lung cancer and secondary drug resistance, has low bioavailability and adverse reactions due to current oral administration. The aim of this study was...

Full description

Bibliographic Details
Main Authors:	Xiaoyan LV, Junjing YIN, Xiucheng YANG, Sha LIU, Kaoxiang SUN
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2018-09-01
Series:	Chinese Journal of Lung Cancer
Subjects:	Afatinib Liposomes Ammonium sulfate gradient method Ultraviolet spectrophotometry Determination of entrapment efficiency
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.02

Similar Items

Development of curcumin liposome formulations using polyol dilution method
by: Lalana Kongkaneramit, et al.
Published: (2016-12-01)

Palbociclib overcomes afatinib resistance in non-small cell lung cancer
by: Huijuan Nie, et al.
Published: (2019-01-01)

Stimulation of Eryptosis by Afatinib
by: Abdulla Al Mamun Bhuyan, et al.
Published: (2018-06-01)

Second-line afatinib administration in an elderly patient with squamous cell carcinoma
by: Hohenforst-Schmidt W, et al.
Published: (2017-03-01)

Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma
by: Naoki Shijubou, et al.
Published: (2021-03-01)

Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
by: Toshiyuki Sumi, et al.
Published: (2021-07-01)

Afatinib Sensibilizes Multidrug-resistant Human Ovarian Cancer Cells to Adriamycin and Related Mechanisms
by: ZHANG Yunqi, et al.
Published: (2018-10-01)

“Liquid elbows” due to afatinib administration
by: Paul Zarogoulidis, et al.
Published: (2017-01-01)

Indirect spectrophotometric determination of diltiazem hydrochloride in pure form and pharmaceutical formulations
by: El-Didamony Akram
Published: (2005-09-01)

Afatinib: new treatment options for lung cancer with activating EGFR mutations
by: M. V. Stepanchenko, et al.
Published: (2015-12-01)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
by: Vavalà T
Published: (2017-11-01)

Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program
by: Tu HY, et al.
Published: (2020-12-01)

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France
by: Pignata M, et al.
Published: (2017-10-01)

Rapid Response to High-Dose, Pulsatile Erlotinib in Afatinib-Refractory Leptomeningeal Carcinomatosis from Adenocarcinoma of the Lung: A Case Report
by: Frank S. Fan
Published: (2016-09-01)

Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways
by: Zhen Liu, et al.
Published: (2021-02-01)

Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non‐small cell lung cancer
by: Xin Nie, et al.
Published: (2021-06-01)

In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma
by: Xue C, et al.
Published: (2016-03-01)

Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients
by: Liu Z, et al.
Published: (2018-10-01)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
by: Hayoung Choi, et al.
Published: (2021-05-01)

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report
by: Zhao Y, et al.
Published: (2021-05-01)

Development of a stable single-vial liposomal formulation for vincristine
by: Mao W, et al.
Published: (2019-06-01)

Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report
by: Jun Nishimura, et al.
Published: (2017-07-01)

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
by: Junyan Tao, et al.
Published: (2020-09-01)

New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
by: Hirsh V
Published: (2017-05-01)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
by: Wan-Ling Tan, et al.
Published: (2018-12-01)

Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib
by: Lu S
Published: (2019-02-01)

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients
by: Wang LY, et al.
Published: (2018-01-01)

Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
by: Karolin Ebert, et al.
Published: (2020-10-01)

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
by: Chiao-En Wu, et al.
Published: (2021-07-01)

A Colorimetric Method to Measure the Amount of Hydroquinone in Liposomal Formulations
by: rabea khoshneviszadeh, et al.
Published: (2019-06-01)

The role of surfactants in the formulation of elastic liposomal gels containing a synthetic opioid analgesic
by: Singh S, et al.
Published: (2016-04-01)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
by: Lin L, et al.
Published: (2020-09-01)

Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data
by: Ashley M. Hopkins, et al.
Published: (2019-06-01)

Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
by: Simone Keller, et al.
Published: (2018-04-01)

Liposomal Formulations for an Efficient Encapsulation of Epigallocatechin-3-Gallate: An In-Silico/Experimental Approach
by: Emiliano Laudadio, et al.
Published: (2018-02-01)

Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced Lung Adenocarcinoma and Review of Literature
by: Hong TAO, et al.
Published: (2014-04-01)

Prospective exosome‐focused translational research for afatinib study of non‐small cell lung cancer patients expressing EGFR (EXTRA study)
by: Yusuke Okuma, et al.
Published: (2019-02-01)

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
by: Lu S, et al.
Published: (2018-11-01)

Comparison of the Efficacy of Two Novel Antitubercular Agents in Free and Liposome-Encapsulated Formulations
by: Nikoletta Kósa, et al.
Published: (2021-02-01)

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer
by: Kazumi Sano, et al.
Published: (2020-04-01)